Expert Opinion on Emerging Drugs
Leading citation impact metric from Clarivate Journal Citation Reports
43 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.8) | 🔵 Computed |
| 2025 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.7) | 🔵 Computed |
| 2024 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.7) | 🔵 Computed |
| 2023 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.4) | 🔵 Computed |
| 2022 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.912) | 🔵 Computed |
| 2021 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 4.191) | 🔵 Computed |
| 2020 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.807) | 🔵 Computed |
| 2019 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.23) | 🔵 Computed |
| 2018 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.579) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Measures cumulative publication volume and citation impact.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
PHARMACOLOGY & PHARMACY | JCRSCIE | 116/356 | Q2 |
PHARMACOLOGY & PHARMACY | JCISCIE | 227/356 | Q3 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 18 | 1 |
| 2025 | 2.7 | 25 | 77 |
| 2024 | 2.7 | 33 | 274 |
| 2023 | 3.4 | 29 | 199 |
| 2022 | 3.912 | 35 | 354 |
| 2021 | 4.191 | 34 | 460 |
| 2020 | 2.807 | 42 | 871 |
| 2019 | 3.23 | 21 | 470 |
| 2018 | 3.579 | 30 | 874 |
| 2017 | — | 25 | 517 |
| 2016 | — | 40 | 1,023 |
| 2015 | — | 48 | 1,440 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Expert Opinion on Emerging Drugs
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics